Loading…
NeuroThera Labs Inc. successfully validated the proprietary workflow.
SciSparc Ltd. announced on July 29, 2026, that its subsidiary NeuroThera Labs Inc. has successfully completed the internal validation of a proprietary quantum sampling workflow designed for clinical trials data analysis.
The validation process confirmed the workflow's effectiveness and reliability for use in clinical trials, marking a significant step forward in SciSparc's technological capabilities.
SciSparc Ltd. has a free float of 57,798 shares and 565,516 shares outstanding.
This summary was generated by AI from public sources and may contain errors. Not financial advice. Trade at your own risk.